The Impact of DNA Tumor Viruses in low-to-middle income countries (LMICS): a literature review.

DNA tumor viruses EBV HBV HPV Kaposi Sarcoma Polyoma

Journal

Tumour virus research
ISSN: 2666-6790
Titre abrégé: Tumour Virus Res
Pays: Netherlands
ID NLM: 101775149

Informations de publication

Date de publication:
06 Jul 2024
Historique:
received: 15 02 2024
revised: 02 07 2024
accepted: 03 07 2024
medline: 9 7 2024
pubmed: 9 7 2024
entrez: 8 7 2024
Statut: aheadofprint

Résumé

DNA viruses are common in the human population and act as aetiological agents of cancer on a large scale globally. They include the human papillomaviruses (HPV), Epstein-Barr virus (EBV), Kaposi sarcoma-associated herpesvirus (KSHV), hepatitis viruses, and human polyomaviruses. Oncogenic viruses employ different mechanisms to induce cancer. Notably, cancer only develops in a minority of individuals who are infected, usually following protracted years of chronic infection. The human papillomaviruses (HPVs) are associated with the highest number of cancer cases, including cervical cancer and other epithelial malignancies. Hepatitis B virus (HBV) and the RNA virus hepatitis C (HCV) are significant contributors to hepatocellular cancer (HCC). Other oncoviruses include Epstein-Barr virus (EBV), Kaposi sarcoma-associated herpes virus (KSHV), human T-cell leukemia virus (HTLV-I), and Merkel cell polyomavirus (MCPyV). The identification of these infectious agents as aetiological agents for cancer has led to reductions in cancer incidence through preventive interventions such as HBV and HPV vaccination, HPV-DNA based cervical cancer screening, antiviral treatments for chronic HBV and HCV infections, and screening of blood for transfusion for HBV and HCV. Successful efforts to identify additional oncogenic viruses in human cancer may provide further understanding of the aetiology and development of cancer, and novel approaches for prevention and treatment. Cervical cancer, caused by HPV, is the leading gynaecological malignancy in LMICs, with high age-standardised incidence and mortality rates, HCC due to HBV is an important cause of cancer deaths, and the burden of other cancer attributable to infections continues to rise globally; hence cancers attributable to DNA viruses have become a significant global health challenge. These viruses hence warrant continued attention and interrogation as efforts to understand them further and device further preventive interventions are critical.

Identifiants

pubmed: 38977263
pii: S2666-6790(24)00013-2
doi: 10.1016/j.tvr.2024.200289
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

200289

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ☐ The author is an Editorial Board Member/Editor-in-Chief/Associate Editor/Guest Editor for [Journal name] and was not involved in the editorial review or the decision to publish this article. ☐ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:The authors have no financial interests/conflicts of interest to declare.

Auteurs

Bothwell Takaingofa Guzha (BT)

Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.

Allen Matubu (A)

University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.

George Nyandoro (G)

Hepatitis Alliance, 2172 Arlington, Hatfield, Harare.

Hamish O Mubata (HO)

Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.

Enos Moyo (E)

School of Public Health Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.

Grant Murewanhema (G)

Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe. Electronic address: gmurewanhema@gmail.com.

Zvavahera M Chirenje (ZM)

University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe; Department of Obstetrics, Gynecology and Reproductive Science, University of California San Francisco, San Francisco, USA.

Classifications MeSH